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Circulating proteins are vital in human health and disease and are frequently used as biomarkers for 
clinical decision-making or as targets for pharmacological intervention. Here we map and replicate 
protein quantitative trait loci (pQTL) for 90 cardiovascular proteins in over 30,000 individuals, 
resulting in 451 pQTLs for 85 proteins. For each protein we further perform pathway mapping to 
obtain trans-pQTL gene and regulatory designations. We substantiate these regulatory findings with 
orthogonal evidence for trans-pQTLs using mouse knock-down experiments (ABCA1, TRIB1) and 
clinical trial results (CCR2, CCR5), with consistent regulation. Finally we evaluate known drug targets, 
and suggest new target candidates or repositioning opportunities using Mendelian randomization. 
This identifies 11 proteins with causal evidence of involvement in human disease that have not 
previously been targeted, including (gene symbols) EGF, IL16, PAPPA, SPON1, F3, ADM, CASP8, 
CHI3L1, CXCL16, GDF15, and MMP12. Taken together these findings demonstrate the utility of large-
scale mapping the genetics of the proteome, and provide a resource for future precision studies of 











Proteins circulating in blood are derived from multiple organs and cell types, and consist of both 
actively secreted and passively leaked proteins. Plasma proteins are frequently used as biomarkers to 
diagnose and predict disease and have been of key importance for clinical practice and drug 
development for many decades. 
Circulating proteins are attractive as potential drug targets as they can often be directly perturbed 
using conventional small molecules or biologics such as monoclonal antibodies1. However, a 
prerequisite for successful drug development is efficacy, which is predicated on the drug target 
playing a causal role in disease. One approach to clarifying causation is through Mendelian 
randomization (MR), which has successfully predicted the outcome of randomized controlled trials 
(RCT) for pharmacological targets such as PCSK9, LpPLA2 and NPC1L1, and is increasingly becoming a 
standard tool for triaging new drug targets2.  
Recent technological developments of targeted proteomic methods have enabled hundreds to 
thousands of circulating proteins to be measured simultaneously in large studies3-6. This has paved 
the way for studies of genetic regulation of circulating proteins using genome-wide association 
studies (GWAS) for detection of protein quantitative trait loci (pQTL), some of which are referenced 
here 3,4,7-9. 
Here, we present a genome-wide meta-analysis of 90 cardiovascular-related proteins, many of which 
are established prognostic biomarkers or drug targets, measured using the Olink Proximity Extension 
Assay CVD-I panel 10 in 30,931 subjects across 14 studies. The identified pQTLs were combined with 
other sources of information to suggest new target candidates underpinned by insights into cis- and 
trans- regulation of protein levels and to evaluate past and present efforts to therapeutically modify 
the proteins analysed in the present investigation. We also show that protein-centric polygenic risk 
scores (PRS) can predict a substantial fraction of inter-individual variability in circulating protein 
levels, explaining a proportion of disease susceptibility attributable to specific biological pathways.  
These are the first results to emerge from the SCALLOP consortium, a collaborative framework for 
pQTL mapping and biomarker analysis of proteins on the Olink platform (www.scallop-
consortium.com). 
Results 
Genome-wide meta-analysis of 90 proteins reveals 467 independent genetic loci 
associated with plasma levels of 85 proteins 
Ninety proteins in up to 21,758 participants from 13 cohorts passed quality control (QC) criteria and 
were available for GWAS meta-analysis [Supplementary Table 1].  We found a total of 401 pQTLs that 
were significant at a discovery P-value threshold conventional for GWAS (P<5x10-8) [Figure 1] 
[Supplementary Table 2]. Conditioning each of these primary pQTLs using the GCTA-COJO software, 
we identified an additional 144 proximal pQTLs that independently surpassed conventional genome-
wide significance (P<5x10-8), termed as secondary pQTLs. We attempted to replicate the primary and 
secondary pQTLs in two independent studies (9,173 participants) whereupon the discovery and 
replication datasets were meta-analysed, leading to 315 primary pQTLs and 136 secondary pQTLs 
surpassing a Bonferroni corrected P-value (P<5.6x10-10). The discovery P-values were used for pQTLs 
absent in the replication dataset (nsnp=25) [Supplementary Table 2].  
Some proteins such as SCF, RAGE, PAPPA, CTSL1 and MPO showed association with more than nine 
primary pQTLs, but most proteins (22 of 85) were associated with 2 primary pQTLs. We also observed 
that some proteins were associated with multiple conditionally significant (secondary) pQTLs such as 
CCL-4 with 4 secondary signals, implicating complex genetic regulation of circulating CCL-4 at the 
CCL4 locus. 
Analysis of trans-pQTLs suggests common mechanisms by which genetic variants 
affect plasma protein levels 
A “best guess” causal gene for each of the CVD-I trans-pQTLs was assigned by a hierarchical approach 
based on analysis of protein-protein interactions (PPI), literature mining, genomic distance to gene 
and manual review of literature around the gene as well as the genomic context of the association 
signal. In total, 326 primary trans-pQTLs were assigned to unique genes and 30 trans-pQTLs were 
assigned more than one gene, with ABO, ST3GAL4, JMJD1C, SH2B3, ZFPM2 showing association with 
the levels of five or more CVD-I proteins [Extended Figure 2A and 2B] [Supplementary Table 2]. 
Extending this analysis to pQTLs from literature expanded the list of genes with five or more protein 
associations to include also KLKB1, GCKR, FUT2, TRIB1, SORT1 and F12 [Supplementary Table 4]. 
Gene ontology (GO) analysis of genes assigned to all significant trans-pQTLs showed functional 
enrichment for chemokine binding, glycosaminoglycan binding, receptor binding and G-protein 
coupled chemoattractant activity [Figure 2C]. A broader classification of genes assigned to both cis- 
and trans-pQTLs [Figure 2A, 2B] [Supplementary Table 2] using a wider set of tools (Online Methods) 
suggested that transcriptional regulation, post-translational modifications, such as glycation and 
sialylation, cell-signalling events, protease activity and receptor binding are potential common 
mechanisms by which trans-pQTLs influence circulating protein levels. The default gene calls and 
paths for the CVD-I trans-pQTLs based on PPI and literature mining can be visualised using the 
SCALLOP CVD-I network tool [Extended Figure 2C] whereas details on the classification of genes are 
available in the Online Methods, [Supplementary Information 1] and [Supplementary Table 3]. 
Evidence of mRNA expression mediating associations with a third of cis pQTLs  
We investigated the overlap of the CVD-I cis- and trans-pQTLs with expression quantitative trait loci 
(eQTL) by a combination of approaches and eQTL studies, including direct genetic lookups and co-
localisation using PrediXcan 11  and SMR / HEIDI 12. For direct lookups, three studies were used: 
LifeLines-DEEP (whole blood), eQTLGen meta-analysis (whole blood and PBMCs) and GTEx (48 tissue 
types). Of 545 pQTLs from [Supplementary table 2], eQTL data were available for 434 SNP-transcript 
pairs, including 168 cis-pQTLs and 266 trans-pQTLs. Of these, 72 (43%) of cis-pQTLs had at least one 
corresponding eQTL (FDR<0.05) in any of the eQTL datasets investigated, implicating 42 of the 75 
proteins with a cis-pQTL. At a more stringent eQTL p-value of P<5x10-8, the percentage with a 
corresponding eQTL was 26 %, similar to some previous reports 13-15 [Supplementary Table 5].  
Co-localisation analysis of CVD-I cis-pQTLs and mRNA levels was performed in selected tissues from 
the GTEx project by first imputing mRNA expression of the CVD-I protein-encoding transcripts using 
the PrediXcan11 algorithm  in one of the SCALLOP CVD-I cohorts (IMPROVE), and then testing imputed 
mRNA levels for association with CVD-I plasma protein levels using linear regression. Twenty-six of 
the 90 CVD-I proteins were associated with their corresponding mRNA transcript (FDR<0.05) in at 
least one of the 20 GTEx tissues investigated [Extended Figure 3]. All 26 proteins were among the 42 
proteins found to also be an eQTL by direct lookups. Proteins CCL4, CD40, CHI3L1, CSTB and IL-6RA all 
associated with their corresponding transcript across five or more tissues whereas proteins ST2 and 
RAGE showed significant association exclusively in lung, and CTSD exclusively in skeletal muscle. 
To further investigate if the CVD-I protein pQTLs overlap with eQTLs, we used the SMR/HEIDI 
methods12, using data from the Consortium for the Architecture of Gene Expression (CAGE) study. 
SMR/HEIDI tests the hypothesis that there is a single variant affecting protein and gene expression 
(pleiotropy or causality), with the alternative hypothesis being that protein and gene expression are 
affected by two distinct variants. In total, 125 associations between 96 genes and 54 proteins were 
identified at an experiment-wise SMR test significance level (PSMR<0.05/8558) and a stringent HEIDI 
test threshold (PHEIDI > 0.01) [Supplementary Table 6], of which 23.2 % were in cis-pQTL regions, such 
as IL-8 and U-PAR. The 96 genes were located in 74 loci, suggesting that pleiotropic associations 
between protein and mRNA expression were present for 18.4 % of significant and suggestive primary 
loci using SMR / HEIDI.  
A minor proportion of cis-acting pQTLs are in high linkage-disequilibrium with 
non-synonymous coding variants 
“Pseudo-pQTLs” caused by epitope effects, i.e. differential assay recognition depending on presence 
of protein-altering variants, is a theoretical possibility for cis-pQTLs and likely dependent on the 
method of protein quantification 4,16. To evaluate the potential for pseudo-pQTLs among the CVD-I 
pQTLs, we investigated presence of protein-altering variants for sentinel variants or variants in high 
linkage disequilibrium with a sentinel variant. Of the 90 proteins, 85 had at least one pQTL, including 
12 with only cis-pQTLs, 10 with only trans-pQTLs and 63 with both cis- and trans-pQTLs. Of the 170 
primary or secondary cis-pQTLs for 75 proteins, 20 cis-pQTLs for 18 proteins had a sentinel variant in 
high linkage disequilibrium (LD; R2>0.9) with a protein-altering variant, which suggests potential to 
affect assay performance [Supplementary Table 2].  
Orthogonal evidence supports causal gene to protein relationships for a subset of 
the CVD-I trans-pQTLs 
Of the 326 trans-pQTLs identified, eight were assigned to gene products targeted by compounds or 
antibodies that have been in clinical development [Supplementary Table 7]. Assuming that trans-
pQTLs represent causal relationships between gene variants and proteins, we hypothesized that the 
downstream CVD-I proteins associated with CVD-I trans-pQTL genes would be modulated on 
therapeutic modification of the gene product. Support for this hypothesis was obtained by previous 
work showing that circulating FABP4 is upregulated upon treatment with glitazones (PPARG 
inhibitors)17; that circulating IL-6 is increased after treatment with tociluzumab18 (IL6R inhibitor) and 
that circulating TNF-R2 is decreased upon infliximab (TNFA inhibitor) treatment in patients with 
Crohn’s disease19, which supports CVD-I trans-pQTLs for these proteins. Along these lines, we present 
novel evidence from a clinical trial supporting our observations that a CCR5 variant is a trans-pQTL 
for plasma CCL-4 and a variant in CCR2 is a trans-pQTL for plasma MCP-1 [Supplementary table 2]. 
CCR5 and CCR2 are targeted in combination by the small-molecule dual-inhibitor PF-04634817 20. To 
test whether dual inhibition of CCR5 and CCR2 resulted in a change of circulating CCL-4 and MCP-1 
respectively, we measured these proteins in 350 type 2 diabetes patients in a randomized, double-
blind, placebo-controlled phase-II trial evaluating the efficacy of PF-04634817 in diabetic 
nephropathy (NCT01712061). In addition, we also measured known or suspected ligands of CCR5 and 
CCR2, including CCL-3, CCL-5 (RANTES) and CCL-8, and 5 additional proteins that were present on the 
Olink CVD-I panel, and for which assays were readily available. Compared to placebo, we observed a 
9.25-fold increase in circulating MCP-1 levels (p < 0.0001) and a 2.11-fold increase in circulating CCL4 
levels (p < 0.0001) at week 12 [Figure 3A]. An alternative ligand for CCR-2; CCL-8 did not change 
following exposure to PF-04634817, and neither did other CCR-5 ligands, such as CCL-5 (RANTES) and 
CCL-3. Moreover, EN-RAGE, FGF-23, KIM-1, myoglobin and TNFR-2 were unchanged following PF-
04634817 exposure [Extended Figure 4]. We conclude that CVD-I trans-pQTLs at CCR5 and CCR2 were 
concordant with the effects of PF-04634817 in human.  
Two of the genes implicated by CVD-I trans-pQTLs, ABCA1 and TRIB1 for circulating SCF levels, were 
also investigated in the mouse. Mice with liver-specific or whole-body knockdown of ABCA121 and 
TRIB122 respectively showed decreased plasma levels of SCF compared to matched wild-type controls 
[Figure 3B], concordant with the human CVD-I trans-pQTLs.  
Mendelian randomization analysis revealed 25 CVD-1 proteins causal for complex 
traits with strong evidence  
To identify potential causal disease pathways indexed by proteins, we conducted an MR analysis of 
85 proteins across 38 outcomes. 25 proteins showed strong evidence of causality for at least one 
disease or phenotype and an additional 24 proteins showed intermediate evidence of causality. 
[Figure 4A] [Extended Figure 7] [Supplementary Figure 1]. Using open-source information 
(clinicaltrials.gov)  (www.ebi.ac.uk/chembl/)  (www.drugbank.ca/) (www.opentargets.org) and 
Clarivate Integrity (integrity.clarivate.com), we identified records on past or present clinical drug 
development programs for 14 of the 25 proteins, all of which have been in phase 2 trials or later 
[Supplementary Table 7]. Of the 14 proteins, seven proteins were targeted for an indication different 
from the phenotype implicated by our MR analysis. Eleven of the 25 proteins have never been 
targeted in clinical trials, but may provide new promising target candidates for indications closely 
related to the traits in the MR analysis. 
Several published MR findings were confirmed, including that IL6RA variants associated with higher 
circulating levels of interleukin-6 (IL-6) and soluble IL6-RA were associated with lower risk of coronary 
heart disease (CHD), rheumatoid arthritis (RA) and atrial fibrillation but higher risks of atopy, such as 
asthma and eczema23. We also replicated previous findings suggesting a causal contribution of IL-1ra 
to rheumatoid arthritis (RA) but an inverse causal relationship with cholesterol levels 24, and a 
protective role of genetically higher MMP-12 against stroke 4,25. 
Some novel MR observations included higher levels of CD40 protein and increased risk of RA, higher 
MMP-12 and increased risk of eczema, and higher TRAIL-R2 proteins levels and prostate cancer. 
Further, Dkk-1 has been targeted by a humanised monoclonal antibody (DKN-01) in clinical trials for 
advanced cancer (NCT01457417, NCT02375880), and was in our study causally linked to higher risk of 
bone fractures and lower risk of estimated bone mineral density (eBMD). In addition, strong 
evidence for protective roles of PLGF in CHD, CASP-8 in breast cancer and ST2 in asthma was 
observed. RAGE was causally linked to several traits, including lower body mass index (BMI) and a 
corresponding lower risk of type 2 diabetes (T2D), higher total cholesterol and triglycerides and 
higher risk of prostate cancer and schizophrenia. A small molecule brain penetrant RAGE inhibitor 
was tested in a phase 2 trial of Alzheimer’s disease (NCT00566397), but was stopped early for futility. 
We saw no strong signal for Alzheimer’s disease (or vascular disease) in our MR analysis. Our findings 
identify potential target-mediated effects across multiple other complex phenotypes that might 
manifest in beneficial and/or harmful effects on patients receiving RAGE-modifying therapies. 
We also collated observational evidence for 23 of the 50 protein-trait pairs identified as causal in the 
MR analysis [supplementary table 10]. The direction of effect inferred from observational studies was 
concordant with the effect direction from MR estimates for 12 pairs.   
Heritability analysis and polygenic risk scores (PRS) demonstrates large 
differences in genetic architecture 
We calculated SNP-heritability contributed by the major reported loci (major loci hSNP2, any pQTL 
included in [supplementary table 2]), as well as additional genome-wide SNP-heritability (polygenic 
hSNP2) for each protein included in the entire SCALLOP CVD-I meta-analysis. We observed a large 
range of different genetic architectures: Differences in magnitude of the genetic component (hSNP2) 
ranged from 0.01 (EGF) to 0.46 (IL-6RA). Differences in the contribution from non-genome-wide 
significant SNPs ranged from essentially monogenic (e.g. IL-6RA) to others showing considerable 
locus heterogeneity with genetic contributions originating entirely from a polygenic background with 
no single dominating locus (e.g. PDGF-B and Galanin) [Figure 5].  
In addition, we calculated the out of sample variance explained in the independent Malmo Diet and 
Cancer (MDC) study (N=4,678) both for genome-wide significant loci (major loci V.E.PRS), as well as 
additional variance explained by adding PRS (polygenic V.E.PRS) [Figure 5]. The protein PRS’ applied in 
the MDC study for 11 proteins exceeded 10 % of variance explained (V.E.PRS) and the PRS’ for another 
14 proteins exceeded 5 % of variance explained, suggesting that the genetic contribution to inter-
individual variability of CVD-I protein levels is considerable.    
A polygenic risk score for circulating ST2 levels shows a dose-response 
relationship with asthma 
Since circulating ST2 showed strong evidence of causation in asthma and inflammatory bowel disease 
(IBD) and the polygenic V.E.PRS model for ST2 explained nearly 20 % of its variance, we attempted to 
quantify the effect of the ST2 polygenic V.E.PRS on circulating ST2 levels in the MDC study, and risk of 
asthma and IBD in 337,484 unrelated White British subjects in the UK Biobank. The range of 
circulating ST2 across 11 categories of the ST2 PRS in MDC was nearly 1.2 standard deviations [Figure 
6A]. Corroborating the Mendelian randomization analysis, the ST2 PRS showed a strong negative 
dose-response relationship with risk of asthma (p=1.2x10-8) and a positive trend for risk of IBD 
(p=0.13) [Figure 6B and 6C]. Overlaying the linear trends for ST2 levels, asthma and IBD using meta-
regression, an increase in the PRS equivalent to a 1 standard deviation higher circulating ST2, 
corresponded to a 8.6 % (95%CI 3.8%, 13.2%; P=0.004) reduction in the relative risk of asthma and a 
4.3 % (95%CI -3.8%, 13.0%; P=0.263) increase in the relative risk of IBD [extended Figure 8]. 
Reverse Mendelian randomization identifies widespread causal relationships, 
where complex phenotypes affects CVD-I proteins 
To investigate whether genetic susceptibility (liability) to complex disease and phenotypes causally 
alter circulating levels of CVD-I proteins, we also performed MR using 38 complex phenotypes 
(including continuous risk factors, such as adiposity and clinical outcomes, such as T2D) as exposure 
and CVD-I protein levels as outcomes. All CVD-I proteins were causally altered by at least one 
complex phenotype. BMI and estimated glomerular filtration rate (eGFR) causally affected 32 and 29 
of the 85 tested proteins respectively [Figure 7A] [Extended Figure 7] [Supplementary Figure 2]. BMI 
seemed to causally affect protein levels in both positive and negative directions, whereas only REN 
(renin) was causally decreased with genetically higher eGFR. In an effort to elucidate whether these 
estimates were recapitulated in simple observational analyses, we compared effect estimates from 
linear regression analyses of associations of BMI and eGFR with each respective CVD-I protein in one 
of the participating study cohorts (IMPROVE). The correlation between the observational and MR 
estimates were high for BMI (R=0.78), and more modest for eGFR (R=0.50) [Figure 7B-C].  
Discussion 
Using a meta-analysis approach including >30,000 individuals, we identified and replicated 315 
primary and 136 secondary pQTLs for 85 circulating proteins to yield new insights for translational 
studies and drug development. Our study demonstrates that pQTLs can be harnessed to enhance 
evaluation of therapeutic hypotheses for protein targets, and to support those hypotheses with basic 
insights into potential protein regulatory pathways and biomarker strategies. However, we also 
observed large differences between proteins in relation to genetic architecture, suggesting that the 
relative strength to apply these strategies is likely protein-dependent.  
Our pQTL-based framework was developed to address several key challenges associated with drug 
development, including a) mapping of protein regulatory pathways, b) identification of new target 
candidates c) repositioning of drugs, d) target-associated safety and e) matching of target 
mechanisms to patients by protein biomarkers or genetic PRS’ [Figure 8].  
The mapping of trans-pQTLs, which typically have smaller effects on protein levels [Extended Figure 
9], was aided by the large SCALLOP discovery sample size, yielding on average 4 independent pQTLs 
per protein. A causal gene was assigned for each trans-pQTL to generate hypotheses that can be 
further tested using in vitro or in vivo perturbation experiments. The robustness of causal gene 
assignments for a few selected trans-pQTLs was demonstrated using samples from a randomised 
controlled trial testing a dual small-molecular inhibitor of the protein products of assigned genes 
(CCR5, CCR2) and transgenic mice with liver-specific knockdown of assigned genes (ABCA1, TRIB1). 
Although further studies will be needed for orthogonal validation of most of the genes assigned from 
the CVD-I trans-pQTLs, several of the implicated genes have previously been identified as regulators 
of some of the CVD-I proteins including CASP126, NLRC426 and GSDMD27 for IL-18, FLT128 for PLGF, 
ADAM17 29 for TNFR1 and SLC34A130 for FGF-23 [Supplementary Table 2].   
Further, we attempted to estimate the proportion of pQTLs that were likely to be driven by effects 
on mRNA expression, using multiple eQTL approaches and datasets. The lowest estimate was 
obtained with SMR/HEIDI, suggesting that 18.4 % of pQTLs were also eQTLs whereas direct look-up 
and co-localisation analysis using PrediXcan yielded estimates between 26 % - 29 %. We conclude 
that the majority of pQTLs identified for the CVD-I proteins were not explained by eQTLs. 
Clinical-stage targeting with any drug modality was reported for 35 of the 90 proteins on the Olink 
CVD-I panel [Supplementary Table 7]. Our MR analysis identified 11 proteins with causal evidence of 
involvement in human disease that have not previously been targeted. Among those, four proteins 
were causal for a disease phenotype and did not show strong evidence of inverse causality with 
another phenotype (increasing specificity for intended indication), including CHI3L1 and SPON1 for 
atrial fibrillation and PAPPA for type-2 diabetes. Strong causal evidence was also identified for 
proteins targeted in phase-2 or later development. The MR evidence was concordant with drug 
indications for several protein targets but for some also suggested alternative indications or that 
monitoring of target-associated safety might be warranted. Monoclonal antibodies that block the 
CD40 ligand binding to CD40 – a critical element in T cell activation – have been shown to have 
positive clinical effects in patients with autoimmune diseases; but increased risk of 
thromboembolism precluded further clinical development31. These observations from clinical trials 
are in line with our findings that genetically lower levels of CD40 are associated with lower risk of RA, 
but higher risk of stroke. There are ongoing efforts to modify CD40L antibodies to retain efficacy 
while avoiding thromboembolism 31. However, our results suggest that decreasing circulating CD40 
levels may have target-mediated beneficial effects on RA risk, while increasing the risk of ischemic 
stroke, i.e. that the increased risk of thromboembolism (manifest as stroke) is an on-target adverse 
effect. TRAIL-R2 is a key receptor for TRAIL, which has been shown to selectively drive tumour cells 
into apoptosis. Therefore, considerable effort to agonise TRAIL-R2 for treating cancers has been 
made in the past years32. We demonstrated that increased circulating TRAIL-R2 is protective against 
prostate cancer, which may suggest that this cancer type should be investigated in clinical trials 
evaluating the efficacy of TRAIL-R2 agonists. 
Biomarkers can be broadly classified as generic biomarkers for disease risk or prognosis, or as 
biomarkers reflecting the activity of specific disease processes or biology. Biomarkers that enable 
matching of target mechanisms to patient subgroups with greater than average benefit from 
treatment are enablers of precision medicine. We showed that CCR2/CCR5 small-molecule inhibition 
modulated circulating levels of CCL-4 and MCP-1, which may suggest that trans-pQTLs can guide 
selection of exploratory biomarkers to monitor the efficacy of target mechanisms. We also identified 
multiple complex traits causally affecting circulating protein levels. For example, eGFR and BMI 
causally influenced over 1/3 of the CVD-I proteins, suggesting that future biomarker studies should 
consider these traits as potential confounders. Moreover, the causal phenotype-to-protein 
associations may represent pathway-related causality to the complex phenotype of interest; or 
alternatively, ‘reverse causality’ which might pose an opportunity to evaluate implicated proteins as 
surrogate biomarkers for efficacy in interventional trials 33. We found that higher BMI causally 
lowered RAGE, while higher circulating levels of RAGE were causally linked to a lower risk of T2D. 
Thus, developing a hypothetical therapeutic to increase RAGE might represent a mechanism by 
which it is possible to off-set the risk of T2D arising from the global increases in obesity.  
Protein-centric PRS’ may allow stratification of individuals with genetic propensity for high circulating 
protein levels. Only 10 % of the protein-centric PRS’ explained 10 % or more of the protein variance 
in the independent replication cohort, including ST2, a prognostic biomarker for heart failure34. ST2 
showed evidence of inverse causality in asthma and positive causality in IBD. By constructing a 
genome-wide polygenic risk score for ST2 levels from the MDC study, applying it to the UK Biobank 
and comparing asthma and IBD prevalence across eleven quantiles of the ST2 PRS, estimated the 
magnitude of ST2 increase required to decrease the risk of asthma to similar levels as individuals in 
the highest ST2 PRS category. Such use of PRS for proteins may be expanded to other disease 
endpoints and may be of use in precision medicine, to guide which patients may obtain most benefit 
from drugs that pharmacologically alter individual proteins. 
In conclusion, our findings provide a comprehensive toolbox for evaluation and exploitation of 
therapeutic hypothesis and precision medicine approaches in complex disease. Such approaches 
provide an excellent opportunity to rejuvenate the drug development pipeline for new treatments. 
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Figure and table legends 
 
Figure 1. Chromosomal location of all associations discovered. Cis-pQTLs are shown in red (bold) 
and trans-pQTLs in blue if they are significant at a conventional GWAS significance threshold of 
P<5x10-8. The gene annotations refer to the gene closest to the pQTL. A version of this figure with 
only loci selected according to the criteria for Mendelian randomization is available as [Extended 
figure 1]. 
Figure 2. Classification of cis- and trans-pQTL genes. A. The gene ontology label of all cis-pQTL 
genes, i.e. the protein-encoding genes. B. The gene-ontology label of all best-guess trans-pQTL genes. 
C. Gene set enrichment analysis of genes assigned to all significant trans-pQTLs, showing the top-
gene sets from the Gene Ontology set Molecular Function. 
Figure 3. Clinical trial in humans and knock down experiment in mice corresponds to trans pQTL 
effects. A) In humans treated with a small molecule dual-inhibitor of CCR5 and CCR2 (PF-04634817) 
the induction of MCP-1 and CCL4, mirrors the observed CVD-I trans-pQTLs. Box plots elements are 
according to standards for box-and-whisker diagrams. B) In mice, knockdown of ABCA1 or TRIB1 
resulted in decreased circulating SCF levels mirroring CVD-I trans-pQTLs for SCF. Shown in the plot 
are SCF levels of individual mice represented by circles (wild-type in blue and transgenic mice in red) 
and the median level per group. P-value is calculated using a two-sided T-test. 
Figure 4. Main findings of Mendelian randomization analysis. A. Heatmap of Mendelian 
randomization analyses of 38 complex traits. ICD-10 chapter of indication and clinical trial stage 
indicated for each target B. Forest plot showing CVD-I proteins with strong evidence of causality in 
the Mendelian randomization analysis. Drug development abbreviations: PC: pre-clinical, Ph1: Phase 
1, Ph2: Phase 2, Ph3: Phase 3, post-MA: post-marketing authorisation. ICD-10 chapters of disease: A-
B: infectious and parasitic; C-D: neoplasms; D: blood and immune; E: endocrine, nutritional and 
metabolic; F: mental and behavioural; G: nervous system; H: eye, adnexa, ear and mastoid; I: 
circulatory system; J: respiratory system;  K: digestive system; L: skin and subcutaneous tissue; M: 
musculoskeletal and connective tissue; N: genitourinary; O: pregnancy, childbirth, puerperium; P: 
perinatal; Q: congenital, deformations and chromosomal; R: clinical and lab findings; S-T: injury, 
poisoning;  U: provisional assignment (new diseases unknown aetiology); V-Y: external causes; Z: 
health status & health services 
Figure 5. SNP heritability and variance explained by genetics. A. SNP-Heritability in the SCALLOP 
consortium discovery cohorts stratified by contributions major loci (light red) and polygenic effects 
(dark red). In the independent MDC cohort, additional variability explained by adding major loci (light 
blue) and polygenic risk scores (dark blue). Significance was reported according to the LDSC algorithm 
(blue) or a linear regression model (red). B. Differences in how protein levels are affected by 
polygenic (non-genome-wide significant) loci vs major loci, shown for both the SCALLOP consortium 
discovery cohorts as hSNP2 and for the MDC cohort as variability explained. 
Figure 6.  Mendelian randomization using polygenic risk scores. A. Association of a polygenic risk 
score (PRS) with ST2 levels in the independent MDC cohort. B. Association of the ST2 PRS with 
asthma in the UK-biobank. B. Association of the ST2 PRS with inflammatory bowel disease (IBD) in 
the UK-biobank. The ST2 PRS was divided into 11 quantiles, with the middle group (quantile number 
6) as the reference category. Effect estimates are presented as quantile-specific mean differences 
(ST2) and odds ratios (asthma and IBD) relative to the reference category. 
Figure 7. Mendelian randomization with proteins as outcome. A. Heatmap showing the causal 
estimates of 38 complex traits on CVD-I protein levels. B. Correlation between beta-values for 
association between body mass index and circulating levels of CVD-I proteins in the IMPROVE cohort, 
and causal estimates from the Mendelian randomization analysis of body mass index genetic liability 
on same CVD-I proteins. C. Same as B but for estimated glomerular filtration rate. 
Figure 8. Protein-trait relationships that support target validation, repositioning, target-mediated 
safety and new candidates for drug development. For more information, see data presented in 


























The full summary statistics of the Olink CVD-I protein GWAS have been deposited at the SCALLOP-
CVD-I online resource, allowing access to interactive SCALLOP-CVD-I tools and unrestricted download 
access for secondary analyses. Additionally, a full copy has been deposited at  
https://doi.org/10.5281/zenodo.2615265 for long-term retention, as well as with GWAS catalog. A 
copy of the polygenic scores have been deposited at the PGS catalog. 
Online Methods 
Selection of proteins 
Proteins for the Olink PEA CVD-I panel were selected by mining the literature for protein biomarkers 
associated with cardiovascular risk or prognosis in human observational studies and in animal models 
and by bringing in protein biomarker suggestions from leading cardiovascular disease researchers 10.  
The list of proteins curated from these sources was then pruned down based on availability of high-
quality antibodies and relative abundance of the proteins in human plasma. 
Intra- and inter-plate coefficients of variation (CV) of the CVD-I panel are available from Olink 
Proteomics AB (https://www.olink.com/resources-support/document-download-center/). In 
addition, we calculated the inter-plate coefficient of variation using data from a pooled plasma 
sample in one of the participating cohorts -the IMPROVE study. The mean inter-plate CV was 
averaged across proteins was 16.6 %, (range 11 % -26 %) [Supplementary Table 1]. 
Cohorts and data collection 
Summary statistics from GWAS of Olink CVD-I proteins were obtained from 13 cohorts of European 
ancestry. The details of all study cohorts are shown in [Supplementary Table 9]. Together the cohorts 
included a total of 21,758 individuals; although the average per-protein sample size was 17,747, 
since not all proteins passed quality control (QC) in all cohorts. Each cohort provided data imputed to 
1000 Genomes Project phase 3 reference or later or to the Haplotype Reference Consortium (HRC) 
reference, which resulted in the testing of 21.4M SNPs. Because imputation schemes varied by 
cohort, this resulted in an average of 20.3M SNPs under investigation for each protein. 
Each cohort applied quality control measures for call rate filters, sex mismatch, population outliers, 
heterozygosity and cryptic relatedness as documented in [Supplementary Table 8]. Prior to running 
the genetic analyses, NPX values of proteins (on the log2 scale) were rank-based inverse normal 
transformed and/or standardised to unit variance, thus avoiding potential Olink batch-differences 
between cohorts. Genetic analyses were conducted using additive model regressions, with 
adjustment for population structure and study-specific parameters [Supplementary Table 8]. Forest 
plots of cohort-specific effects are available for all significant and suggestive pQTLs using the online 
tool. Each contributing cohort uploaded the resulting summary statistics in a standardized format 
using a secure computational cluster provided by Neic Tryggve (https://neic.no/tryggve/). All meta-
analysis was performed in duplicate at two different research centres using completely separate 
bioinformatic pipelines (L.F. and S.G.). 
Data cleaning and meta-analysis 
A per-protein filtering threshold of >80% samples above the Olink detection limit was applied to each 
cohort, leaving data on 90 of the 92 proteins to be analysed. The remaining files had an average of 
3% missing samples (per cohort statistics available in [Supplementary Table 8]). Minor allele 
frequencies were compared with those reported in 1000 Genomes EUR. A per-SNP filter was applied 
based on imputation quality level (at default setting for respective imputation algorithm) and minor 
allele count (at least 10 alleles per cohort). This resulted in the omission of 10% of the SNPs. Finally, 
meta-analysis was performed using METAL (2011-03-25) 35, applying the inverse-variance weighted 
approach (i.e. the STDERR option). Throughout the manuscript, P-values from this test are reported 
as-is, with multiple testing burden handled through appropriate thresholds. Cis-pQTLs were defined 
as a signal within 1 Mb of the gene encoding the protein and all other signals were defined as trans-
pQTLs. See [extended figure 5] for flow chart overview of meta analysis.  
Replication analyses 
We sought to replicate the findings in the Malmö Diet and Cancer (MDC) population-based cohort 
with 4,678 individuals, and in the Swedish Mammography Cohort Clinical (SMCC, part of the Swedish 
national research infrastructure SIMPLER described at www.simpler4health.se) population-based 
study of 4,495 women. In MDC, genotypes were imputed to the Haplotype Reference Consortium 
reference (HRC Unlimited v1.0.1) and data were analysed using linear regression in EPACTS 3.3.0 
(linear Wald test). The genotypes in SMCC were measured using Illumina’s Global Screening Array 
and were imputed up to HRC v1.1 and 1000G phase3 (v5), and linear regressions of rank-based 
inverse-normal transformed protein values adjusting for age, storage time, and PC1-15 were 
performed using PLINK v2 (4 Mar 2019).  
Conditional and joint association analysis  
To identify secondary signals at the 401 loci reported in [Supplementary table 2], we performed 
analyses conditioning on the primary signal using conditional-joint analysis in GCTA (version 1.26.0) 
36,37. The Stanley cohort was chosen as an ancestrally well-matched LD-reference cohort. Meta-
analysis summary data were processed with filtering for MAF (0.01) and r2 (<0.001) to ensure that 
secondary association signals identified were not driven by LD with the primary signal.  See 
[Extended figure 6] for a flow chart of signal selection criteria. 
Cross-reference of pQTLs with other complex traits 
For each pQTL association, we searched PubMed and the EBI GWAS catalogue (URL: 
https://www.ebi.ac.uk/gwas/ : November 2018) for published SNPs with any complex trait within 
10kb or having an LD of r2 >= 0.85. 
Comparison between eQTLs and pQTL 
To identify eQTL that corresponded to each pQTL, we used three independent eQTL studies: 
LifeLines-DEEP 38, GTEx39 and eQTLGen40. Each SNP-protein pQTL pair was first converted to SNP-gene 
pairs using Olink platform protein identification and the gene annotation of Ensembl v91. Then, the 
significance of eQTLs for these SNP-gene pairs was assessed in three eQTL datasets, using two 
different cut-offs: a stringent genome-wide significance threshold (P<5x10-8) and a nominal 
significance of P<0.05.  
In the eQTL dataset of LifeLines-DEEP, individual-level whole blood RNA-seq, protein and genotype 
data were available. This allowed for a direct comparison of the concordance of blood eQTLs and 
pQTLs. To do so, we re-tested eQTL associations for all pQTL pairs, using a previously published 
pipeline 41. The resulting eQTLs were considered genome-wide significant if it passed the 
permutation-based FDR <0.05 level, or to be nominally significant if the P-value was < 0.05. 
In the eQTL datasets of GTEx v7 and eQTL-Gen, we did not have access to individual level data. Thus, 
the comparisons were conducted using publicly available eQTL results.  In these datasets, we 
considered an eQTL genome-wide significant if it was within the reported genome-wide significant 
list, and nominally significant if it had a nominal P-value < 0.05. Altogether, if one pQTL pair had at 
least one significant eQTL effect in any dataset irrespective of allelic direction it was considered an 
overlapping pQTL-eQTL pair. 
Expression SMR analysis 
We performed an SMR and HEIDI (heterogeneity in dependent instruments) analysis12 to identify the 
expression levels of genes that were associated with protein abundance through pleiotropy using 
pQTL summary statistics from this study and cis-eQTL summary data from published studies42,43.  
The eQTL summary data used in the SMR analysis were from the Consortium for the Architecture of 
Gene Expression (CAGE), comprising 38,624 normalized gene expression probes and ~8 million SNPs 
from 2,765 blood samples. The eQTL effects were in standard deviation (SD) units of expression 
levels. We excluded the gene probes in the major histocompatibility complex (MHC) region and 
included only the gene probes with at least one cis-eQTL at P<5×10−8 (a basic assumption of SMR), 
resulting in 9,538 gene expression probes.  
The SMR test uses a SNP instrument (i.e., the top associated eQTL) to detect association between 
two phenotypes (i.e., gene and protein in this case). The HEIDI test utilises LD between the SNP 
instrument and other SNPs in the cis-region to distinguish whether the association identified by the 
SMR test is driven by a set of shared genetic variants between two traits (pleiotropic or causal model) 
or distinct sets of variants in LD (linkage model)12. Only the associations that surpassed the genome-
wide significance level of the SMR test (PSMR < 0.05 / m with m being the number of SMR tests) and 
were not rejected by the HEIDI test (PHEIDI > 0.01) were reported as significant.  
PrediXcan and transcript-wide association of CVD-I protein levels 
Imputation of gene expression was performed in the IMPROVE study. After standard quality control, 
genotypes were pre-phased using Eagle2, and then subsequently imputed by minimac4 using the 
1000 Genomes reference. A filter on RSQ 0.8 and minor allele frequency 0.01 was set on the imputed 
genotypes prior to prediction with PrediXcan, which used 44 tissue models based on GTEx v7.  
Using protein data collected on the CVD-I chip in the same individuals, the associations between 
protein levels in plasma and the predicted expression of their respective coding gene across 20 
tissues (from the PrediXcan model) were modelled by a linear model in R. False discovery rate were 
estimated based on Q-values (using the R package qvalue). In total, 64 genes in one to 18 tissues 
were tested for associations between protein levels and predicted expression. Heatmaps were 
constructed (using the pheatmap package in R) for any gene with a significant association (FDR<0.05) 
in at least one tissue. 
Systems Biology 
Two sets of network analysis were performed, one using the protein-protein interaction (PPI) data 
from the inBio Map™ (InWeb_InBioMap) and one using significant associations from text-mining 
(TM). These two networks each had 13,033 and 14,635 nodes, respectively; and 147,882 and 193,777 
edges, respectively. In both setups, the shortest path between any of the cis-gene intermediaries to 
the protein was identified; altogether 12,436 pairs were compared. Of the 372 trans-pQTL 
associations reported in [Supplementary Table 2], 335 associations had both cis-gene intermediaries 
and plasma protein in the network allowing their analysis. The likelihood of a path arising by chance 
was calculated by permutation sampling, using 1,000,000 random networks were generated with a 
conserved degree distribution. A new algorithm was developed for de novo random network 
generation, which generated random networks with a nearly conserved degree distribution in a 
feasible time-frame. Further details are available in [Supplementary Information 1]. 
Assignment of cis-intermediary genes 
To assign the most plausible causal gene for each of the CVD-I trans-pQTLs we applied a hierarchical 
approach based on analysis of InWeb_InBioMap PPI, TM, and genomic distance between gene and 
lead variant at each locus. Results were then manually reviewed by literature, gene expression 
analysis (proteinatlas.org) and published pQTLs which led to the re-assignment of 52 genes. The 
algorithmic gene assignment was overruled or complemented for instances when the assigned gene 
was different from the gene assigned by multiple prior studies [Supplementary table 4]. Gene 
Ontology analysis of most plausible genes was performed using the DAVID bioinformatics tools and 
the GO MF gene set definition, with default settings. The Panther pathway tool, Uniprot and the 
Human Protein Atlas were used to classify the genes according to basic functional class (see URLs). 
Human in-vivo validation of trans-pQTLs 
PF-04634817 is a competitive dual inhibitor of CCR2 and CCR5 receptors.  In the recent B1261007 
study, (ClinicalTrials.gov Identifier: NCT01712061), samples were collected from subjects with 
diabetic nephropathy and treated with PF-04634817 for 12 weeks. CCL-2 (MCP-1) was measured in 
serum by ELISA at Eurofins (The Netherlands). CCL4 (MIP-1b) and CCL-8 were measured in plasma 
using Luminex assays (Bio-Rad, Berkeley, CA). CCL5 (RANTES), was measured in plasma as part of a 
multi-analyte panel at Myriad Rules Based Medicine (Austin, TX). 
Mouse in-vivo validation of trans-pQTLs 
Plasma from transgenic- and matched control mice were randomised on a PCR plate. The samples 
included five mice with targeted deletion of hepatocyte ABCA121 together with five matched control 
mice, three mice with whole-body TRIB122 knockdown and three controls and four mice with liver-
specific knockdown of TRIB1 and four matched controls. Protein levels of stem cell factor (SCF) was 
measured using the Olink PEA Mouse exploratory panel according to the manufacturer’s instruction 
(Olink Proteomics, Uppsala, Sweden). The plasma levels of SCF were normalised against average 
protein concentrations using information on an additional 91 proteins. TRIB1 whole-body and liver-
specific mice were analysed jointly as were the respective wild-type controls. The median plasma 
levels of SCF were compared using the Mann-Whitney U test for unpaired samples.  
Mendelian randomization 
To study the causal effects of the protein on selected disease outcomes, we performed two-sample 
Mendelian randomization analyses. We used between-study heterogeneity to guide the instrumental 
variable selection. In the presence of between-study heterogeneity (P-het<9x10-5), variants had to 
surpass a Bonferroni-corrected p-value threshold in discovery (P<5.6x10-10) and show nominal 
significance (P<0.05) in the replication studies (9,173 individuals), with directionally concordant beta 
coefficients. In the absence of between-study heterogeneity we included variants showing 
conventional genome-wide significance (P<5x10-8) in a meta-analysis of the discovery and replication 
datasets.  From these, we created two sets of instrumental variables (IVs) for each of the 85 proteins 
with variants reaching multiple testing-corrected significance in our discovery GWAS: (a) cis IVs 
including one or more independent variants (LD r2=0.001 within ±1Mb of the transcript boundaries of 
the gene encoding the protein); and (b) pan IVs including all independent (LD r2=0) variants 
associated with the protein, i.e. combining cis and trans pQTLs. The per-allelic beta coefficients from 
the main GWAS analyses were used as weights in the IVs. For the outcomes, we obtained the 
relevant SNP-to-trait summary statistics from publicly-available GWAS as outcomes [Supplementary 
Table 9]. When lead variants from our main GWAS were not available in these summary statistics, we 
replaced them with proxies (LD r2>0.85). For each individual SNP-protein and SNP-outcome 
association, we generated an instrumental variable Wald ratio estimate, with standard errors 
obtained using the delta method. When the instrument included more than one SNP, summary IV 
estimates were generated by combining individual SNP Wald estimates by inverse-variance weighted 
fixed-effect meta-analysis. We report associations with a Benjamini-Hochberg false discovery rate 
(FDR) ≤ 5%, applied separately to summary estimates from cis-pQTL and pan-pQTL IVs, using pooled 
estimates for all 38 diseases. We graded the evidence of causality using a framework outlined in 
[Extended Figure 7], using the following categories: strong (cis-IV estimate FDR≤ 5%); intermediate 
(pan-IV estimate FDR≤ 5% with: (i) no heterogeneity between cis-IV estimate and pan-IV estimate; 
and (ii) no evidence of the MR estimate being unduly influenced by a trans-pQTL in leave-one-out 
analysis); or weak (pan-IV estimate FDR≤ 5% but: no cis-pQTL IV available; heterogeneity between 
cis- and all- IVs; or evidence of undue influence by a trans-pQTL). Heterogeneity between pan-IV and 
cis-IV estimates were calculated using Cochran’s Q tests, with P<0.05 denoting evidence against the 
null hypothesis, and applying a Bonferroni adjustment for multiple testing. Mendelian randomization 
was conducted in duplicate by two separate analysts and analyses were performed in Stata 
(StataCorp, Texas, USA) version 13.3 using the mrivests, metan and multproc commands and R. Of 
the 2437 IV estimates derived using cis-pQTL instruments across the 85 proteins and 38 outcome 
traits, the IV estimates of 50 protein-to-disease associations met the FDR≤5% (corresponding to an 
uncorrected P≤1.1x10-3). Of the 3044 IV estimates composed using all pQTL instruments, 281 IV 
estimates met FDR≤ 5% (corresponding to P≤ 4.7x10-3; [Figure 4A]).  
Heritability analyses 
We estimated the total SNP-heritability (hSNP2) for the plasma level of each protein from the summary 
statistics of each individual GWAS by summing the contributions from two independent partitions of 
the SNPs: primary major loci and polygenic background. We defined the variance explained by primary 
major loci (major loci hSNP2) as the sum of the estimated variance explained (2*2*f*(1-f)), where f is 
the minor allele frequency, and owing to the fact that the phenotypic variance has been standardized 
across lead SNPs indexing all primary genome-wide significant loci. We used LDSC regression44 to 
estimate the contribution of the polygenic background (polygenic hSNP2) for each protein, which we 
define as the contribution of all loci not indexed by a genome-wide significant lead SNP. LDSC 
regression is known to perform poorly when large effect, major genes are present, as it was derived 
under the assumption of a simple polygenic genetic architecture44. To account for this and avoid 
double counting the variance explained by major loci through LD surrogates, prior to estimating the 
LDSC regression polygenic hSNP2, we censored all SNPs within 10 Mb of genome-wide significant lead 
SNPs for all primary loci.   
Polygenic risk score calculation 
Polygenic risk scores were derived using LDpred algorithm45, which adjusts the effect of each SNP allele 
for those of other SNP alleles in linkage disequilibrium (LD) with it, and also takes into account the 
likelihood of a given allele to have a true effect according to a user-defined parameter, which we used 
as all 7 default LDpred-settings, with values from 1 through 1x10-5. The algorithm was directed to use 
HapMap3 SNPs that had a minor allele frequency >0.05, Hardy-Weinberg equilibrium P>1e-05 and 
imputation score >0.95. Variance explained in the independent MDC-study was tested according to a 
step-wise model, first including non-genetic covariates, then additional variability explained by adding 
SNPs from genome-wide significant SNPs (major loci V.E.PRS), and then additional variability explained 
by adding the 7 LDpred-derived scores as additional covariates (polygenic V.E.PRS).  
ST2 polygenic risk score for asthma and inflammatory bowel disease in the UK 
biobank 
Prior to analysis subjects who were not White British (based on self-reported ancestry in 
combination with genetic PCA) in the maximum unrelated subset were filtered out. All bi-allelic SNPs 
with MAF >= 1% and MaCH rsq >= 0.8 were kept. The Z-score transformed LDpred PRS (wt2) for ST2 
was calculated as described for MDC in 337,484 White British UK Biobank participants. Association 
with asthma and IBD were tested using logistic regression adjusting for age, sex, PC1-10, genotype 
batch using either the continuous PRS or the PRS quantile-bins as predictors. The UK Biobank 
protocol has been described previously46 and is available online (https://www.ukbiobank.ac.uk). The 
genotype quality control (QC), phasing, and imputation was performed centrally and has been 
previously described 47. Outcomes (defined based on self-reported data at baseline and/or the 
inpatient and death registry [including primary and secondary causes as well as prevalent and 
incident disease]) Asthma: Self-reported touchscreen (6152), self-reported nurse interview (20002), 
or ICD-10 "J45". Conflicting self-reported results set to missing unless "J45" was reported.   
Inflammatory bowel disease: nurse interview (20002) or ICD-10 K50-K52. 
Meta-regression analysis for ST2 PRS, asthma and IBD 
We estimated the per-quantile and per-SD associations of the weighted PRS for ST2 (MDC study) on 
risks of asthma and IBD (UK Biobank) by taking the quantile associations with ST2, asthma and IBD 
and conducting meta-regression analyses whereby the dependent variable was the quantile-specific 
logOR and corresponding SE of asthma or IBD and the independent variable was the quantile specific 
beta coeffient for ST2. This was conducted using the "metareg" package in STATA SE v13.1 
(Statacorp, USA). Plots from the metaregression are presented in [Extended Figure 8]. 
Observational evidence 
Observational evidence for the CVD-I proteins showing strong evidence of causality in Mendelian 
randomization was collated from literature or by de-novo analysis in the IMPROVE cohort 
[supplementary table 10]. To identify evidence from literature, we searched for the protein name or 
aliases in combination with the implicated trait trait/disease in PubMed. For clinical outcome traits, 
only those reported as “significant” by the paper were included, and the table provides the 
directional information provided. For quantitative outcome traits, standardised betas and p-values 
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